#India #Mumbai #Lupin Limited #Nanomi B.V. #PrecisionSphere

A New Era for Injectable Products

In a significant move towards advancing the pharmaceutical landscape, Lupin Limited announced the launch of a strategic partnership program designed to expand the reach of its innovative injectable platform, PrecisionSphere™. This initiative is particularly timely, following the recent approval from the U.S. Food and Drug Administration (FDA) for the first product developed using this platform. The aim is to collaborate with companies that are keen on extending the lifecycle of their pharmaceutical products, whether they are still under development or already available in the market.

Understanding PrecisionSphere™

PrecisionSphere™ stands out in the realm of long-acting injectable medications, emphasizing safety and effectiveness. This cutting-edge platform seeks to tackle the prevalent issues of poor medication adherence, which lead to loss of sales and therapeutic failures in the pharmaceutical industry. Its technological superiority lies in producing uniform drug particles that enhance injectability, a significant advancement over conventional long-acting injectable technologies that typically generate particles of varying sizes.

Moreover, PrecisionSphere™ not only optimizes drug concentrations but also ensures a consistent release of medications over prolonged periods, ranging from several weeks to a few months. This offers a dual advantage: it simplifies the treatment of patients and improves therapeutic outcomes.

Benefits of Strategic Collaborations

Fabrice Egros, President of Business Development at Lupin, expressed the optimism surrounding this new initiative. He stated, “With the validated capabilities of PrecisionSphere and our proven track record in establishing several strategic partnerships each year, we are poised to enhance patient access to innovative long-acting injectable treatments through new, global collaborations.”

The main thrust of Lupin’s strategy is to bring together entities interested in leveraging the benefits of long-acting formulations. By facilitating these collaborations, Lupin aims to ensure that patients receive timely and effective treatments, thus enhancing overall healthcare delivery.

Shahin Fesharaki, Lupin's Chief Scientist, added, “PrecisionSphere™ reflects our commitment to innovation and utilizes our regulatory expertise, scalable manufacturing capabilities, and flexible collaboration models to lower barriers for developers of long-acting injectable products.” Such an approach is expected to enable partners to swiftly introduce advanced injectable solutions across various therapeutic areas, potentially extending their patent lives.

Addressing Patient Needs

The platform's design ensures that healthcare professionals can manage drug administration effectively while maintaining the therapeutic doses needed for optimal patient outcomes. Moreover, for patients, the reduced frequency of injections not only provides convenience but potentially enhances adherence to treatment regimens, leading to improved overall health results.

About Lupin Limited

Operating globally out of its headquarters in Mumbai, India, Lupin Limited is a leading pharmaceutical company with a vast portfolio that spans over 100 markets worldwide. The company specializes in a broad range of pharmaceuticals, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. With a workforce of over 24,000 employees across seven R&D centers and 15 state-of-the-art manufacturing sites, Lupin is dedicated to improving patient health outcomes through its various subsidiaries, including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To learn more about Lupin and its groundbreaking initiatives, visit www.lupin.com or connect on LinkedIn. For details about Nanomi B.V., visit www.nanomi.com.